Targeted RNA Sequencing Market Overview, Size, and Industry Analysis, By Type (Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing, Others), By Application (Cancer Gene Sequencing, Inherited Disease Screening, Drug Development, Forensic Genomics, 16S ribosomal RNA (rRNA) Sequencing), Regional Insights and Forecast to 2035

Targeted RNA Sequencing Market Overview

Global Targeted RNA Sequencing Market size is estimated at USD 5268.36 million in 2026, set to expand to USD 9338.96 million by 2035, growing at a CAGR of 6.57%.

The Targeted RNA Sequencing Market is experiencing sustained development as pharmaceutical companies, molecular research laboratories, and biotechnology organizations increasingly adopt advanced sequencing technologies to investigate gene expression, RNA variants, and disease-associated molecular changes. Cancer Gene Sequencing represents approximately 43% of the analytical application allocation, reflecting strong demand for transcript-level information in oncology research and biomarker investigation. Targeted RNA sequencing allows researchers to concentrate sequencing resources on selected transcripts, genes, or biologically relevant regions rather than analyzing every RNA molecule within a sample. The market includes Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing, and Others, with these categories encompassing different approaches to focused nucleic acid analysis.

The United States represents an important Targeted RNA Sequencing Market because of its established genomics research infrastructure, pharmaceutical industry, molecular oncology programs, and concentration of sequencing technology manufacturers. North America accounts for approximately 36% of the analytical regional allocation, with the United States contributing the largest regional share. American research organizations increasingly use targeted sequencing to investigate gene fusions, abnormal transcript expression, and molecular pathways associated with disease. Cancer research institutions require reliable methods for examining selected transcripts within clinical research specimens, including archived tissue samples where RNA quality may be limited. Illumina introduced Rapid RNA Prep during 2026, offering sequencing-ready RNA libraries in as little as two hours for supported workflows. 

Key Findings

• Market Driver: Growing demand for molecular oncology research supports targeted RNA sequencing adoption, with Cancer Gene Sequencing representing approximately 43% of analytical application demand, driven by fusion detection and biomarker investigation.
• Major Market Restraint: Sample degradation, workflow complexity, and specialized bioinformatics requirements constrain adoption, with approximately 34% of analytical implementation risks associated with RNA quality, processing consistency, and data interpretation.
• Emerging Trends: Rapid RNA library preparation, automated nucleic acid processing, and targeted transcript enrichment are transforming sequencing workflows, with Enrichment Sequencing accounting for approximately 33% of analytical technology demand, supporting efficient biomarker analysis and molecular research.
• Regional Leadership: North America leads the Targeted RNA Sequencing Market with approximately 36% analytical share, supported by established genomics laboratories, pharmaceutical research, sequencing manufacturers, and molecular oncology programs.
• Competitive Landscape: Illumina leads the report's analytical competitive allocation with approximately 21% market share, supported by sequencing platforms, RNA library preparation technologies, bioinformatics capabilities, and established research relationships.
• Market Segmentation: Enrichment Sequencing leads the analytical technology segmentation with approximately 38% share, supported by focused transcript capture, efficient sequencing resource allocation, and biomarker research applications.

Targeted RNA Sequencing Market Latest Trends

The Targeted RNA Sequencing Market is increasingly influenced by rapid library preparation, automated nucleic acid processing, flexible target capture, and improved sequencing sensitivity. Enrichment Sequencing accounts for approximately 33% of the analytical technology allocation, highlighting demand for methods that concentrate sequencing activity on biologically relevant transcripts. Researchers increasingly use targeted approaches when investigating defined gene sets or searching for transcript alterations associated with particular diseases. Hybridization-based enrichment can support the recovery of selected sequences from complex libraries, including certain degraded or low-input specimens when appropriate protocols are used. Illumina introduced Rapid RNA Prep during 2026, supporting messenger RNA, total RNA, and targeted.

Another important trend involves real-time target selection, advanced bioinformatics, and flexible sequencing methods that reduce dependence on fixed laboratory panels. Amplicon Sequencing represents approximately 32% of the analytical technology allocation, reflecting continued demand for focused amplification-based approaches. PCR-based targeted sequencing remains relevant when laboratories require analysis of predefined transcripts or fusion events. Oxford Nanopore Technologies is also advancing adaptive sampling, which enables software-directed selection of target regions during sequencing.

Targeted RNA Sequencing Market Dynamics

Driver

"Growing demand for molecular biomarkers accelerates targeted RNA sequencing adoption."

The primary driver of the Targeted RNA Sequencing Market is increasing demand for molecular information that can support cancer research, biomarker identification, and investigation of disease-related gene activity. Cancer Gene Sequencing represents approximately 43% of the analytical application allocation, highlighting the importance of oncology within targeted transcript analysis. Cancer researchers increasingly investigate gene fusions, altered expression patterns, and abnormal RNA processing as part of molecular characterization. Targeted sequencing can concentrate analytical resources on transcripts relevant to a specific research question, potentially allowing deeper coverage of selected targets than a broader approach using comparable sequencing capacity. Different techniques are selected according to target complexity, RNA quality, and desired molecular information. Amplicon methods can provide focused analysis of known sequences, while enrichment methods can capture broader collections of transcripts.

Restraint

"RNA degradation and complex analytical requirements restrict wider laboratory adoption."

A major restraint affecting the Targeted RNA Sequencing Market is the difficulty of obtaining reliable results from samples with limited quantity or compromised RNA integrity. Approximately 34% of the analytical implementation-risk allocation concerns sample quality, library preparation consistency, workflow complexity, and bioinformatics requirements. RNA is susceptible to degradation during collection, storage, extraction, and handling. Archived tissue specimens may also contain fragmented or chemically modified RNA, complicating certain sequencing procedures. Laboratories must therefore evaluate extraction methods, sample quality, and library preparation compatibility before selecting a targeted assay. Insufficient or uneven coverage can reduce confidence in low-abundance transcript detection. Amplification-based methods may introduce representation biases when primers perform differently across targets. Enrichment workflows require appropriate probe design and hybridization conditions. Data interpretation also demands expertise in quality control, alignment, and transcript identification. Continued market development depends on more reliable sample preparation and accessible analytical tools.

Opportunity

"Precision oncology and streamlined sequencing workflows create new research opportunities."

One of the strongest opportunities in the Targeted RNA Sequencing Market is the expansion of focused molecular analysis for cancer research and pharmaceutical development. Cancer Gene Sequencing accounts for approximately 43% of analytical application demand, highlighting opportunities for targeted transcript panels and associated analytical systems. Researchers increasingly investigate RNA fusions and expression alterations that may complement genomic mutation information. Targeted sequencing approaches can reduce the amount of irrelevant data generated when the research objective concerns a defined transcript collection. Library preparation improvements also support analysis of limited or degraded samples where suitable assay performance has been demonstrated. Manufacturers increasingly develop automated processing and integrated data interpretation solutions. Illumina, Roche, Qiagen, and Thermo Fisher Scientific maintain technologies relevant to different stages of these workflows. Continued interest in molecular biomarkers supports opportunities for sequencing instruments, reagents, and analytical software

Challenge

"Accurate transcript interpretation and assay reproducibility challenge advanced sequencing workflows."

A central challenge in the Targeted RNA Sequencing Market is ensuring that sequencing data accurately represent the transcripts present in the original biological specimen. Amplicon Sequencing accounts for approximately 32% of the analytical technology allocation, making primer design, amplification bias, and sequence coverage important considerations. RNA molecules can vary substantially in abundance, and low-expression transcripts may be difficult to detect consistently. Reverse transcription efficiency can also influence the composition of prepared libraries. Researchers must distinguish genuine biological differences from technical variation introduced during sample processing. Appropriate controls and analytical thresholds are essential when interpreting targeted sequencing results. Gene fusion analysis introduces additional complexity because abnormal transcript junctions may require specialized alignment and filtering methods. Manufacturers increasingly develop quality control tools and improved analytical software. Continued technological development must balance sensitivity, accuracy, reproducibility, and operational efficiency.

Targeted RNA Sequencing Market Segmentation

By Types

Exome Sequencing: Exome Sequencing represents approximately 17% of the analytical Targeted RNA Sequencing Market technology allocation and includes focused investigation of coding-region transcripts through suitable RNA preparation and target capture approaches. This classification must be distinguished from conventional DNA exome sequencing, which analyzes genomic coding regions rather than expressed RNA molecules. RNA exome workflows may be useful when researchers seek transcript information from selected coding genes. These methods can support studies involving gene expression, transcript abnormalities, and selected molecular pathways. Researchers must consider RNA quality because expression levels and transcript availability influence results. Manufacturers increasingly develop capture systems and library preparation technologies suited to challenging samples. Appropriate analytical pipelines help distinguish transcript-derived findings from genomic sequence information. Continued demand for focused coding-transcript analysis supports the segment.

Enrichment Sequencing: Enrichment Sequencing accounts for approximately 38% of the analytical Targeted RNA Sequencing Market technology allocation and maintains the leading position because of demand for focused transcript capture and efficient sequencing resource utilization. Enrichment methods commonly use complementary probes or related techniques to select nucleic acid sequences associated with predefined research targets. These approaches can support analysis of gene panels, selected transcript collections, and molecular regions associated with particular biological questions. Researchers increasingly evaluate enrichment methods according to specificity, coverage uniformity, input requirements, and library compatibility. Hybridization-based capture is relevant when a broader target collection must be examined without individually amplifying every sequence. Manufacturers increasingly develop customizable probes and automated library preparation methods. Bioinformatics tools support analysis of captured transcripts and identification of relevant molecular changes. Continued oncology and pharmaceutical research supports segment leadership.

Amplicon Sequencing: Amplicon Sequencing represents approximately 32% of the analytical Targeted RNA Sequencing Market technology allocation and remains important for focused analysis of known transcript regions and selected fusion events. Amplicon methods use designed primers to amplify relevant sequences before sequencing. RNA-based workflows generally require conversion of RNA into complementary DNA before amplification with conventional DNA polymerases. These approaches are suitable for research questions involving defined molecular targets. Manufacturers develop multiplex assays that can examine several selected sequences within one processing workflow. Appropriate primer design is essential because variations in amplification efficiency can influence target representation. Researchers increasingly evaluate assay sensitivity, specificity, and compatibility with low-input samples. Continued demand for focused oncology sequencing supports this segment.

Others: Others accounts for approximately 13% of the analytical Targeted RNA Sequencing Market technology allocation and includes specialized approaches outside the principal Exome Sequencing, Enrichment Sequencing, and Amplicon Sequencing categories. These methods may involve customized transcript analysis, alternative target-selection techniques, and research-specific sequencing configurations. Oxford Nanopore Technologies provides adaptive sampling capabilities that allow selected targets to be prioritized during sequencing without conventional physical enrichment in applicable workflows. Such techniques require careful distinction between DNA-directed and RNA-directed methods. Researchers increasingly evaluate flexible analytical approaches for projects that do not fit established panel designs. Continued sequencing innovation supports specialized demand.

By Applications

Cancer Gene Sequencing: Cancer Gene Sequencing represents approximately 43% of the analytical Targeted RNA Sequencing Market application allocation and maintains the leading position because of extensive demand for molecular oncology research. Researchers increasingly investigate gene fusions, abnormal transcript expression, and RNA processing alterations associated with different cancer types. Targeted RNA sequencing can help concentrate analytical resources on biologically relevant transcripts. Oncology research laboratories also use RNA findings to complement DNA mutation data where suitable. Sample quality is particularly important when studying archived tumor tissue. Manufacturers increasingly develop library preparation systems and targeted panels suited to limited or degraded material. Bioinformatics software supports fusion identification and transcript-level analysis. Continued investment in precision oncology research strengthens application leadership.

Inherited Disease Screening: Inherited Disease Screening accounts for approximately 18% of the analytical Targeted RNA Sequencing Market application allocation and includes research into transcript abnormalities associated with suspected inherited genetic conditions. RNA sequencing can provide functional information concerning expression changes and abnormal splicing. Researchers may investigate whether genomic variants influence transcript formation or stability. Suitable tissue selection is important because relevant genes may not be expressed equally in every biological sample. Targeted approaches allow investigation of selected transcript collections when a specific research question has been defined. Results require careful interpretation alongside available clinical and genomic information. Continued development of molecular genetics research supports this application.

Drug Development: Drug Development represents approximately 24% of the analytical Targeted RNA Sequencing Market application allocation and supports pharmaceutical research involving biological pathways, potential biomarkers, and experimental treatment responses. Researchers examine RNA expression changes to better understand molecular mechanisms affected by candidate compounds. Targeted sequencing can support studies focused on predefined gene sets and biological processes. Pharmaceutical organizations increasingly prioritize reproducible sample preparation and reliable data analysis. Gene expression information may also support investigation of resistance mechanisms and therapeutic targets. Manufacturers increasingly develop workflows compatible with different experimental sample types. Continued pharmaceutical innovation supports application demand.

Forensic Genomics: Forensic Genomics accounts for approximately 7% of the analytical Targeted RNA Sequencing Market application allocation and includes specialized research into RNA-based molecular information potentially relevant to forensic investigations. RNA markers may provide information about biological sample characteristics under suitable analytical conditions. However, RNA degradation and variable sample quality can limit performance. Researchers must establish appropriate validation before applying a technique within operational forensic casework. Targeted sequencing offers opportunities to study selected transcripts where their biological relevance is understood. Chain-of-custody requirements and laboratory quality standards remain important considerations. Continued forensic molecular research supports specialized interest.

16S ribosomal RNA (rRNA) Sequencing: 16S ribosomal RNA (rRNA) Sequencing represents approximately 8% of the analytical Targeted RNA Sequencing Market application allocation and includes specialized microbial research involving ribosomal RNA-associated targets. The term commonly refers to sequencing of the bacterial 16S rRNA gene, often performed through DNA-based amplicon sequencing. Direct sequencing of 16S rRNA molecules is a distinct RNA-oriented approach and should not be confused with conventional gene sequencing. Researchers use 16S-related analysis to investigate microbial diversity and taxonomic composition. Appropriate target selection and analytical methods depend on the biological question. Manufacturers provide sequencing reagents and computational tools suitable for microbial research. Continued microbiology research supports demand.

Targeted RNA Sequencing Market Regional Outlook

North America

North America represents approximately 36% of the analytical Targeted RNA Sequencing Market allocation and maintains the leading regional position. The United States contributes through established genomics laboratories, pharmaceutical research organizations, advanced sequencing manufacturers, and molecular oncology programs. Research institutions increasingly adopt targeted transcript analysis to investigate disease-associated molecular changes. Manufacturers continue developing efficient library preparation technologies and integrated sequencing systems. Clinical research organizations also evaluate RNA analysis within broader precision medicine studies. Continued investment in genomics infrastructure supports regional leadership.

North American sequencing innovation increasingly emphasizes shorter laboratory workflows and improved analytical accessibility. Illumina introduced Rapid RNA Prep during 2026, supporting library preparation in as little as 2 hours. The development provides an example of how manufacturers are reducing preparation complexity for supported RNA applications. Research laboratories increasingly prioritize workflow reproducibility and data quality. Continued product development supports regional activity.

Europe

Europe accounts for approximately 27% of the analytical Targeted RNA Sequencing Market allocation and remains an important center for pharmaceutical research, molecular genetics, and advanced laboratory technologies. Germany, France, Switzerland, the United Kingdom, and other European economies contribute through established research institutions and biotechnology companies. Laboratories increasingly investigate targeted transcript analysis for oncology and inherited disease research. Manufacturers emphasize analytical reliability and efficient sample processing. Regulatory requirements also influence development of research workflows intended for possible future clinical applications. Continued genomics research supports regional demand.

European sequencing technology development is increasingly influenced by flexible platforms and improved molecular analysis. Roche launched AXELIOS 1 during June 2026, introducing a research sequencing platform based on sequencing-by-expansion technology. The system is designed to support multiple nucleic acid applications, including RNA research. European laboratories increasingly assess new sequencing platforms according to accuracy, throughput, and workflow compatibility. Continued technological innovation supports market participation.

Asia-Pacific

Asia-Pacific represents approximately 29% of the analytical Targeted RNA Sequencing Market allocation and provides significant opportunities associated with expanding biotechnology research, pharmaceutical development, and genomics infrastructure. China, Japan, India, South Korea, and other regional economies contribute through research laboratories and growing molecular testing capabilities. Institutions increasingly investigate gene expression and biomarker analysis for disease research. Local manufacturing and laboratory automation investment can improve access to advanced sequencing technologies. Research partnerships also support technical expertise development. Continued expansion of molecular science programs strengthens regional market activity.

Asia-Pacific laboratories increasingly seek efficient sequencing workflows and flexible analytical software. Qiagen conducted a targeted sequencing research webinar during May 2026, highlighting its ongoing technical engagement in precision oncology. Approximately 24% of global analytical demand comes from Drug Development, demonstrating the importance of pharmaceutical research within sequencing applications. Regional organizations increasingly invest in standardized sample processing and data interpretation. Continued innovation supports market development.

Middle East and Africa

Middle East and Africa accounts for approximately 5% of the analytical Targeted RNA Sequencing Market allocation and offers opportunities associated with expanding molecular research infrastructure and specialized laboratory development. Gulf countries increasingly invest in biotechnology and genomics programs, while African research institutions investigate molecular approaches to disease studies. Adoption varies according to equipment availability, laboratory expertise, and research funding. Targeted methods may help laboratories concentrate sequencing resources on relevant molecular questions. Manufacturers increasingly evaluate technical support and distribution arrangements for emerging markets. Continued investment in research infrastructure supports gradual adoption.

Regional demand is increasingly influenced by oncology research and laboratory modernization. Cancer Gene Sequencing accounts for approximately 43% of global analytical application demand, illustrating the importance of targeted molecular research. Laboratories increasingly seek dependable sequencing systems and appropriate analytical training. Sample handling and computational infrastructure remain important implementation considerations. Continued biotechnology development supports regional opportunities.

Rest of World

Rest of World represents approximately 3% of the analytical Targeted RNA Sequencing Market allocation and includes selected Latin American and other research markets outside the principal regional classifications. Brazil, Mexico, Argentina, Chile, and surrounding economies contribute through molecular biology laboratories, academic research, and pharmaceutical development. Targeted sequencing adoption depends on equipment availability, technical expertise, and research investment. Organizations increasingly investigate methods that provide focused molecular information without unnecessarily broad sequencing requirements. International partnerships can improve access to advanced research technology. Continued genomics infrastructure development supports market participation.

Regional sequencing research increasingly emphasizes efficient targeted assays and accessible analytical workflows. Enrichment Sequencing represents approximately 38% of global analytical technology demand, illustrating the importance of focused molecular analysis. Laboratories increasingly evaluate sample preparation methods suited to available equipment and research objectives. Bioinformatics training and technical support remain important requirements. Continued investment in molecular research creates opportunities for specialized sequencing technologies.

List of Top Targeted RNA Sequencing Market Companies

• Illumina, Inc.
• F. Hoffmann-La Roche AG
• Qiagen
• Thermo Fisher Scientific, Inc.
• Oxford Nanopore Technologies
• Genenexus

Top 2 Companies with Highest Market Share

• Illumina, Inc.: Illumina represents approximately 21% of the report's analytical competitive allocation, supported by its established sequencing instruments, RNA library preparation products, and bioinformatics capabilities. The company provides technology used across transcriptomics, cancer research, and molecular biology applications. During 2026, Illumina introduced Rapid RNA Prep, enabling preparation of sequencing-ready RNA libraries in as little as two hours under supported conditions.
• Thermo Fisher Scientific, Inc.: Thermo Fisher Scientific represents approximately 17% of the report's analytical competitive allocation, supported by its Ion Torrent sequencing technology, targeted assay portfolio, laboratory automation capabilities, and extensive life sciences distribution network. Its Oncomine product portfolio includes research assays designed to examine relevant DNA and RNA molecular alterations. 

Investment Analysis And Opportunities

Investment opportunities in the Targeted RNA Sequencing Market increasingly concentrate on streamlined library preparation, sensitive transcript detection, automated laboratory processing, and advanced bioinformatics. Enrichment Sequencing represents approximately 38% of the analytical technology allocation, highlighting demand for focused molecular workflows. Manufacturers increasingly invest in capture technologies and preparation systems designed to support reliable recovery of selected transcripts. Improvements in processing time can help laboratories complete research workflows more efficiently. Automated extraction and library preparation systems also create opportunities for reducing manual handling. Pharmaceutical and oncology researchers increasingly seek solutions compatible with challenging specimens and variable sample volumes. Investment in data analysis tools can improve interpretation and quality monitoring. Continued demand for efficient molecular research supports opportunities across instruments, reagents, and software.

New Product Development

New product development in the Targeted RNA Sequencing Market increasingly emphasizes faster RNA library preparation, improved sequencing flexibility, and simplified laboratory workflows. Illumina introduced Rapid RNA Prep during 2026, supporting preparation of sequencing-ready libraries in as little as 2 hours for compatible sample types and applications. The technology is designed to support messenger RNA, total RNA, and targeted RNA workflows through related preparation procedures. Roche also introduced KAPA RNA EvoPrep, providing a streamlined library preparation approach with a specified processing time of approximately three and a half hours. Manufacturers increasingly emphasize compatibility with limited-input and degraded RNA. Automated processing technologies also support consistent library preparation. Continued product innovation helps researchers manage complex sequencing projects more efficiently.

Five Recent Developments

• May 2026 – Qiagen Advances Targeted Precision Oncology Research Education: Qiagen delivered a targeted sequencing in precision oncology webinar program on May 19, 2026, supporting technical education around focused molecular analysis. The initiative strengthened access to research knowledge and workflow guidance, although it was not a new RNA sequencing product launch.
• June 2026 – Illumina Expands Rapid RNA Library Preparation Technology: Illumina presented its newly launched Rapid RNA Prep technology during a June 25, 2026, webinar, demonstrating a streamlined workflow capable of generating sequencing-ready libraries in as little as 2 hours. The technology supports targeted RNA sequencing alongside other RNA research applications.
• June 2026 – Roche Launches Advanced Sequencing By Expansion Platform: F. Hoffmann-La Roche AG launched AXELIOS 1 on June 29, 2026, introducing a flexible research-use sequencing system built around its proprietary sequencing-by-expansion technology. The platform supports research applications including RNA sequencing and same-day whole-genome analysis.
• August 2026 – Thermo Fisher Maintains RNA Sequencing Reagent Supply: Thermo Fisher Scientific documented August 2026 quality-control certificates for multiple batches of its Ion Xpress RNA-Seq Barcode 1-16 Kit, supporting continued availability of RNA library preparation reagents. This is a documented supply activity rather than a confirmed new targeted RNA product launch.
• October 2026 – Oxford Nanopore Releases Adaptive Sampling Research Guide: Oxford Nanopore Technologies published updated adaptive sampling guidance on October 19, 2026, describing real-time target selection and customizable digital panels. The development supports flexible targeted sequencing research, although the documented examples focus primarily on DNA-directed workflows rather than a newly launched RNA-specific assay.

Report Coverage of Targeted RNA Sequencing Market

The Targeted RNA Sequencing Market report examines focused transcript analysis, target enrichment, amplification workflows, library preparation, and bioinformatics. Application coverage considers cancer research, inherited disease investigation, drug development, forensic genomics, and ribosomal RNA analysis, distinguishing RNA-based methods from related DNA sequencing approaches. The study also reviews sample quality, gene fusion detection, reproducibility, and laboratory workflow selection.

Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, examining genomics infrastructure, research capabilities, and technology accessibility. Competitive analysis reviews instrument, reagent, automation, and software portfolios. Additional coverage explores RNA degradation, preparation bias, data interpretation, technical training, research partnerships, and product development.